Cure8 research brief
Noninvasive blood indices are appealing because they’re easier than colonoscopy. This study tests whether two such indices (SII and HALP) reliably reflect endoscopic activity in ulcerative colitis and whether azathioprine treatment changes their performance.
Adult patients with ulcerative colitis, gastroenterology clinicians monitoring disease activity, and researchers focused on IBD biomarkers.
This study evaluated two blood-derived inflammatory indices (SII and HALP) against endoscopic activity in ulcerative colitis using retrospectively reviewed patient data and standard endoscopic activity scores.
The authors found that CRP remained the strongest individual biomarker; SII showed an association with endoscopic activity but only modest discrimination, while HALP added little diagnostic value. Azathioprine use did not significantly modify the associations.
How this matters: the paper suggests SII and HALP can be considered adjunctive inflammatory indices but should not replace CRP or endoscopy for assessing endoscopic activity in UC.
Practical note: these findings come from a retrospective single-cohort analysis; SII’s modest improvement over CRP was small and not a substitute for established tests or colonoscopy.
The report is a retrospective clinical study using standard endoscopic scores; CRP remained the strongest single biomarker and SII/HALP provided only modest or limited additional discrimination. Azathioprine did not significantly interact with these indices. The study does not imply these indices can replace endoscopy.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood-based inflammatory ratios like CRP/albumin were associated with higher odds of needing anti‑TNF therapy, colectomy, and longer hospital stays in moderate–severe UC, suggesting potential utility as complementary...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
